PALI · PALISADE BIO, INC.

NasdaqHealthcareBiotechnology

Palisade Bio Inc Is A Clinical-Stage Biopharma Company Focused On Identifying And Developing Therapeutics That Protect The Integrity Of The Intestinal Barrier. Its Portfolio Consists Of A Pali-2108 For The Treatment Of Ibd, Including Uc And Cd, And Is Researching Pali-1908.

HealthcareNasdaqUS

$1.81

+114.2% latest move

Price & move as of the most recent catalyst (Sep 30) — not a live quote.

FLOAT

173.3M

FREE FLOAT %

99%

SHARES O/S

174.3M

MARKET CAP

$277.1M

EXCHANGE

Nasdaq

COUNTRY

PALI Catalyst History

Regulatory and ClinicalAug 6, 2025 · 7:59pm ET

PALIPALISADE BIO, INC.

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with PALI-2108

Company announces positive results for novel PDE4 inhibitor

Be early on the next PALI spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

PALI · PALISADE BIO, INC.

PALI Catalyst History

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with PALI-2108

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with PALI-2108

Palisade Bio Completes SAD Cohorts and Starts MAD Cohorts in PALI-2108 Trial

Palisade Bio Completes SAD Cohorts and Starts MAD Cohorts in PALI-2108 Trial